Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis

被引:35
作者
Gehanno, P [1 ]
Berche, P [1 ]
Danon [1 ]
Darmon [1 ]
Car [1 ]
Amsellem [1 ]
Timsit [1 ]
Amsellem [1 ]
Nemi [1 ]
Tlili [1 ]
Trottin [1 ]
Cambriel [1 ]
Levy [1 ]
Meaux [1 ]
Lafosse [1 ]
Blassin [1 ]
Hamman [1 ]
Lefranc [1 ]
Marsac [1 ]
Reboul [1 ]
Donnadieu [1 ]
Lefebvre [1 ]
AroniodeRon [1 ]
DeloixVericel [1 ]
Duboux [1 ]
Flieder [1 ]
Rousselet [1 ]
Samson [1 ]
Vericel [1 ]
Tsigaridis [1 ]
Popot [1 ]
Jacquin [1 ]
Huart [1 ]
Ebbo [1 ]
Dufour [1 ]
Cornubert [1 ]
Baculard [1 ]
Meunier [1 ]
LopezMoya [1 ]
Vigneron [1 ]
Bonnard [1 ]
Isasa [1 ]
Bourrel [1 ]
Agustin [1 ]
Assous [1 ]
Banal [1 ]
Barrier [1 ]
Betsch [1 ]
Bringart [1 ]
Cassat [1 ]
机构
[1] HOP NECKER ENFANTS MALAD,MICROBIOL LAB,PARIS,FRANCE
关键词
D O I
10.1093/jac/37.suppl_A.105
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In a double-blind, multicentre trial, 382 patients with a diagnosis of acute purulent sinusitis were randomised to receive sparfloxacin 200 mg once daily for 5 days following a loading dose of 400 mg on day 1 (n = 193) or cefuroxime axetil 250 mg twice daily for 8 days (n = 189). Patients were classified as success or failure according to clinical symptoms plus bacteriological and radiological data at the end of treatment and at a follow-up visit. In analyses of the intent-to-treat (n = 374) and evaluable populations (n = 304), the 5 day course of sparfloxacin was at least as effective and well tolerated as the 8 day course of cefuroxime axetil. The success rates at the end of treatment in the evaluable population were 82.6% and 83.2% in the sparfloxacin and cefuroxime axetil groups, respectively. The pathogens isolated most frequently were Haemophilus influenzae (33%) and Streptococcus pneumoniae (28%). Response rates according to the bacterial aetiology of the acute sinusitis were similar in the two treatment groups. Both drugs were well tolerated. The commonest adverse events were gastrointestinal and were reported in 2.6% and 3.8% of sparfloxacin- and cefuroxime axetil-treated patients, respectively.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 21 条
[1]   INVITRO ACTIVITIES OF SPARFLOXACIN, TOSUFLOXACIN, CIPROFLOXACIN, AND FLEROXACIN [J].
BARRY, AL ;
FUCHS, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (05) :955-960
[2]   CLINICAL COMPARISON OF CEFUROXIME AXETIL AND AMOXICILLIN CLAVULANATE IN THE TREATMENT OF PATIENTS WITH ACUTE BACTERIAL MAXILLARY SINUSITIS [J].
CAMACHO, AE ;
COBO, R ;
OTTE, J ;
SPECTOR, SL ;
LERNER, CJ ;
GARRISON, NA ;
MINITI, A ;
MYDLOW, PK ;
GIGUERE, GC ;
COLLINS, JJ .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (03) :271-276
[3]   INVITRO ACTIVITY OF SPARFLOXACIN COMPARED WITH THOSE OF 5 OTHER QUINOLONES [J].
CANTON, E ;
PEMAN, J ;
JIMENEZ, MT ;
RAMON, MS ;
GOBERNADO, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :558-565
[4]   INVITRO ACTIVITY OF SPARFLOXACIN [J].
CHIN, NX ;
GU, JW ;
YU, KW ;
ZHANG, YX ;
NEU, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :567-571
[5]   INVITRO ACTIVITY OF SPARFLOXACIN, A NEW QUINOLONE ANTIMICROBIAL AGENT [J].
COOPER, MA ;
ANDREWS, JM ;
ASHBY, JP ;
MATTHEWS, RS ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :667-676
[6]  
DABERNAT H, 1991, B EPIDEMIOL HEBD, V33, P140
[7]   TREATMENT OF COMMUNITY ACQUIRED ACUTE SINUSITIS - CEFUROXIME AXETIL VS CEFIXIME [J].
GEHANNO, P ;
BOUCOT, I ;
CHICHE, D ;
BERCHE, P .
MEDECINE ET MALADIES INFECTIEUSES, 1991, 21 :61-65
[8]   COMPARISON OF CEFPODOXIME PROXETIL WITH CEFACLOR IN THE TREATMENT OF SINUSITIS [J].
GEHANNO, P ;
DEPONDT, J ;
BARRY, B ;
SIMONET, M ;
DEWEVER, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :87-91
[9]   ANTIBIOTIC-RESISTANCE OF PNEUMOCOCCAL RESPIRATORY-TRACT INFECTIONS IN FRANCE [J].
GESLIN, P ;
FREMAUX, A ;
SISSIA, G .
MEDECINE ET MALADIES INFECTIEUSES, 1992, 22 :74-86
[10]   THE CONCENTRATION OF SPARFLOXACIN IN LUNG TISSUES AFTER SINGLE AND MULTIPLE ORAL DOSES [J].
HONEYBOURNE, D ;
GREAVES, I ;
BALDWIN, DR ;
ANDREWS, JM ;
HARRIS, M ;
WISE, R .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1994, 4 (03) :151-155